News round-up for 15-19 January by DDW Digital Content Editor Diana Spencer.
With seasonal illnesses running amok in the western hemisphere at the moment, it is perhaps not surprising that this week’s news highlights focus on viruses and immunity.
The top stories:
Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants.
A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin.
Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL).
With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination.
Researchers at the University of Arizona Health Sciences say they are one step closer to understanding immunological rejection, a barrier to regenerative medicine, after genetically modifying pluripotent stem cells to evade immune recognition.